Mylan Pharmaceuticals Private Limited recently launched HepBest 25 mg (tenofovir alafenamide, TAF), a once-daily tablet for the treatment of chronic hepatitis B in adults. According to World Health Organization (WHO) estimates, more than 2 billion people worldwide are infected with the hepatitis B virus (HBV), of which more than 240 million have chronic liver infection.
These patients are at risk of developing serious illness and death, largely resulting from liver cirrhosis and liver cancer. HepBest (TAF) is the first drug in eight years to be approved for the management of chronic hepatitis B in India.
TAF demonstrates comparable efficacy with an enhanced renal and bone safety profile as compared to the earlier formulation of tenofovir (tenofovir disoproxil fumarate). TAF also has greater plasma stability, which ensures efficient drug delivery to the site of action.